400 related articles for article (PubMed ID: 17594094)
1. The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity.
Swift LP; Cutts SM; Nudelman A; Levovich I; Rephaeli A; Phillips DR
Cancer Chemother Pharmacol; 2008 Apr; 61(5):739-49. PubMed ID: 17594094
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death.
Swift LP; Rephaeli A; Nudelman A; Phillips DR; Cutts SM
Cancer Res; 2006 May; 66(9):4863-71. PubMed ID: 16651442
[TBL] [Abstract][Full Text] [Related]
3. ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts.
Ugarenko M; Nudelman A; Rephaeli A; Kimura K; Phillips DR; Cutts SM
Biochem Pharmacol; 2010 Feb; 79(3):339-49. PubMed ID: 19737541
[TBL] [Abstract][Full Text] [Related]
4. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide.
Mizutani H; Tada-Oikawa S; Hiraku Y; Kojima M; Kawanishi S
Life Sci; 2005 Feb; 76(13):1439-53. PubMed ID: 15680309
[TBL] [Abstract][Full Text] [Related]
6. Enhancing the antiproliferative effect of topoisomerase II inhibitors using a polypeptide inhibitor of c-Myc.
Bidwell GL; Raucher D
Biochem Pharmacol; 2006 Jan; 71(3):248-56. PubMed ID: 16316634
[TBL] [Abstract][Full Text] [Related]
7. Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy.
Harris LN; Yang L; Liotcheva V; Pauli S; Iglehart JD; Colvin OM; Hsieh TS
Clin Cancer Res; 2001 Jun; 7(6):1497-504. PubMed ID: 11410482
[TBL] [Abstract][Full Text] [Related]
8. Induction of apoptosis by plumbagin through reactive oxygen species-mediated inhibition of topoisomerase II.
Kawiak A; Piosik J; Stasilojc G; Gwizdek-Wisniewska A; Marczak L; Stobiecki M; Bigda J; Lojkowska E
Toxicol Appl Pharmacol; 2007 Sep; 223(3):267-76. PubMed ID: 17618663
[TBL] [Abstract][Full Text] [Related]
9. Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage.
Marx G; Zhou H; Graves DE; Osheroff N
Biochemistry; 1997 Dec; 36(50):15884-91. PubMed ID: 9398321
[TBL] [Abstract][Full Text] [Related]
10. 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage.
Ravid A; Rocker D; Machlenkin A; Rotem C; Hochman A; Kessler-Icekson G; Liberman UA; Koren R
Cancer Res; 1999 Feb; 59(4):862-7. PubMed ID: 10029076
[TBL] [Abstract][Full Text] [Related]
11. A novel use for the comet assay: detection of topoisomerase II inhibitors.
Salti GI; Das Gupta TK; Constantinou AI
Anticancer Res; 2000; 20(5A):3189-93. PubMed ID: 11062742
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation.
Koceva-Chyła A; Jedrzejczak M; Skierski J; Kania K; Jóźwiak Z
Apoptosis; 2005 Dec; 10(6):1497-514. PubMed ID: 16215684
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
14. The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells.
Poljaková J; Eckschlager T; Hrabeta J; Hrebacková J; Smutný S; Frei E; Martínek V; Kizek R; Stiborová M
Biochem Pharmacol; 2009 May; 77(9):1466-79. PubMed ID: 19426684
[TBL] [Abstract][Full Text] [Related]
15. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
[TBL] [Abstract][Full Text] [Related]
16. 123I-ITdU-mediated nanoirradiation of DNA efficiently induces cell kill in HL60 leukemia cells and in doxorubicin-, beta-, or gamma-radiation-resistant cell lines.
Reske SN; Deisenhofer S; Glatting G; Zlatopolskiy BD; Morgenroth A; Vogg AT; Buck AK; Friesen C
J Nucl Med; 2007 Jun; 48(6):1000-7. PubMed ID: 17504875
[TBL] [Abstract][Full Text] [Related]
17. Protection against Adriamycin cytotoxicity and inhibition of DNA topoisomerase II activity by 3,4-dihydroxybenzoic acid.
De Graff WG; Myers LS; Mitchell JB; Hahn SM
Int J Oncol; 2003 Jul; 23(1):159-63. PubMed ID: 12792789
[TBL] [Abstract][Full Text] [Related]
18. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome.
Vispé S; Vandenberghe I; Robin M; Annereau JP; Créancier L; Pique V; Galy JP; Kruczynski A; Barret JM; Bailly C
Biochem Pharmacol; 2007 Jun; 73(12):1863-72. PubMed ID: 17391647
[TBL] [Abstract][Full Text] [Related]
19. Differential actions of aclarubicin and doxorubicin: the role of topoisomerase I.
Bridewell DJ; Finlay GJ; Baguley BC
Oncol Res; 1997; 9(10):535-42. PubMed ID: 9507531
[TBL] [Abstract][Full Text] [Related]
20. [A novel antitumor agent, sobuzoxane (MST-16)].
Tsukagoshi S
Gan To Kagaku Ryoho; 1994 Jun; 21(7):1089-97. PubMed ID: 8002628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
